Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension

被引：1
|
作者：
Tocci, Giuliano [1 ,2 ]
机构：
[1] Univ Rome Sapienza, Dept Clin & Mol Med, St Andrea Hosp, Rome, Italy
[2] IRCCS Neuromed, Pozzilli, Italy
来源：
CARDIOLOGY | 2020年 / 145卷 / 09期
关键词：
ANGIOTENSIN-II RECEPTOR; NEPRILYSIN; GUIDELINES; ALISKIREN; INHIBITOR;
D O I：
10.1159/000508345
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：599 / 600
页数：2
相关论文
共 50 条
  • [1] Sacubitril/valsartan (LCZ696) for the treatment of heart failure
    Gori, Mauro
    Senni, Michele
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2016, 14 (02) : 145 - 153
  • [2] LCZ696 ( Valsartan/Sacubitril) - A Possible New Treatment for Hypertension and Heart Failure
    Andersen, Mathilde Borring
    Simonsen, Ulf
    Wehland, Markus
    Pietsch, Jessica
    Grimm, Daniela
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 118 (01) : 14 - 22
  • [3] Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study
    Izzo, Joseph L., Jr.
    Zappe, Dion H.
    Jia, Yan
    Hafeez, Kudsia
    Zhang, Jack
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2017, 69 (06) : 374 - 381
  • [4] LCZ696 (Sacubitril/Valsartan) Can We Predict Who Will Benefit?
    Dec, G. William
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (19) : 2072 - 2074
  • [5] Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥ 65 Years) With Systolic Hypertension
    Supasyndh, Ouppatham
    Wang, Jian'an
    Hafeez, Kudsia
    Zhang, Ying
    Zhang, Jack
    Rakugi, Hiromi
    AMERICAN JOURNAL OF HYPERTENSION, 2017, 30 (12) : 1163 - 1169
  • [6] Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolledwith amlodipine monotherapy
    Wang, Ji-Guang
    Yukisada, Kimihiko
    Sibulo, Antonio, Jr.
    Hafeez, Kudsia
    Jia, Yan
    Zhang, Jack
    JOURNAL OF HYPERTENSION, 2017, 35 (04) : 877 - 885
  • [7] Cardioprotective effect of LCZ696 (sacubitril/valsartan) experimental acute myocardial infarction
    Ishii, M.
    Kaikita, K.
    Sato, K.
    Sueta, D.
    Fujisue, K.
    Oimatsu, Y.
    Mitsuse, T.
    Hokimoto, S.
    Ogawa, H.
    Tsujita, K.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1412 - 1412
  • [8] Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and Sacubitril in LCZ696 tablets
    Youssef, Rasha M.
    El-Nahass, Sara A.
    Soliman, Sobhi A.
    Younis, Sameh E.
    SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2021, 256
  • [9] Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
    Kulmatycki, Kenneth M.
    Langenickel, Thomas
    Ng, Wai Hong
    Pal, Parasar
    Zhou, Wei
    Lin, Tsu-Han
    Rajman, Iris
    Chandra, Priyamvada
    Sunkara, Gangadhar
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 728 - 739
  • [10] Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
    Jhund, Pardeep S.
    Fu, Michael
    Bayram, Edmundo
    Chen, Chen-Huan
    Negrusz-Kawecka, Marta
    Rosenthal, Arvo
    Desai, Akshay S.
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Solomon, Scott D.
    Swedberg, Karl
    Zile, Michael R.
    McMurray, John J. V.
    Packer, Milton
    EUROPEAN HEART JOURNAL, 2015, 36 (38) : 2576 - 2584
12345